Bradley Chipps, MD: Key Takeaways from AAAAI/WAO

The president of the American College of Allergy, Asthma & Immunology talked the session's future impact, upcoming therapies, and what his favorite lectures were.

What will be the future clinical impact of this year's AAAAI/WAO Meeting?

Bradley Chipps, MD, President, the American College of Allergy, Asthma & Immunology: I would say that the most basic transitional and clinical sciences being presented here will help form the foundation for possible changes to patient care.

Second, we'll then give researchers other ideas for research projects to be done, and then reinforce what we're already doing as being the appropriate standard of care.

What pipeline therapies or developing research will lead the field in the next decade?

We're going to be talking about disease modification, primarily, as using either a subcutaneous immunotherapy, a sublingual immunotherapy, or possibly one of the biologics we're currently using now.

The most likely ones that will be helpful for possible disease modification are Zolaire or Dupixent. They're likely to be strong contenders for that role.

What are your thoughts on the clinical benefits of dupilumab?

Well, Dupixent allows us to treat atopic dermatitis with a monoclonal antibody. The company has filed already for the FDA indication. The specs say we will get it, probably in November of this year, if all goes well with the FDA — which you never know how that's going to end up. But we're probably going to get it. And it will be a game-changer, because it's at-home after the first loading dose in an office, every 2 weeks, and it allows patients to decrease their corticosteroid dose and also decrease the amount of medication they're taking.

What have been the best lectures you've attended this week?

I think the NHLBI session, where the BARD Trial was a trial for the appropriate immunotherapy for asthma in the African American community.

Second is the trial to treat mild-to-moderate exacerbations in asthma in the pediatric community, in a trial called STICKS.

Then finally, the third part of that symposium, Dr. Avraham Beigelman had a very scientific discussion about interaction of the microbiome and how that affects asthma. That was a very good session.Click here to sign up for more MD Magazine content and updates.